Related Experiment Video
Updated: Feb 14, 2026

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
Published on: October 22, 2020
Smoking is not associated with higher prevalence of JC virus in MS patients
Michael Auer1, Gabriel Bsteh2, Harald Hegen2
1Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. michael.auer@i-med.ac.at.
Abstract:
John Cunningham virus (JCV) causes rare, but potentially life-threatening progressive multifocal leukoencephalopathy (PML) in natalizumab-treated multiple sclerosis (MS) patients. Beside JCV index, there is currently no other factor for further risk stratification. Because smoking was reported as potential risk factor for several viral and bacterial infections, we aimed to investigate whether smoking could increase the risk for JCV infection in MS patients. We screened our database of the MS Clinic of the Department of Neurology, Medical University of Innsbruck, Austria, for patients with known smoking status and test result for anti-JCV antibody index as determined by two-step ELISA at Unilabs, Copenhagen, Denmark. In a representative cohort of 200 MS patients with a rate of 36% current smokers plus 6% former smokers, we were not able to detect any association between smoking and JCV status. Furthermore, there was no association between smoking status and anti-JCV antibody index. Smoking does not seem to be a risk factor for JCV infection in MS patients and, therefore, does not represent a suitable marker for PML-risk stratification under treatment with natalizumab.
Insights
Smoking does not increase the risk of John Cunningham virus (JCV) infection in multiple sclerosis (MS) patients. This finding suggests smoking status is not a reliable factor for stratifying progressive multifocal leukoencephalopathy (PML) risk in MS patients undergoing natalizumab treatment.
Area of Science:
- Neuroimmunology
- Virology
- Epidemiology
Background:
- John Cunningham virus (JCV) causes progressive multifocal leukoencephalopathy (PML), a severe neurological condition.
- PML risk is elevated in multiple sclerosis (MS) patients treated with natalizumab.
- Current risk stratification relies primarily on the JCV antibody index, lacking additional predictive factors.
Purpose of the Study:
- To investigate the potential association between smoking status and JCV infection in MS patients.
- To determine if smoking could serve as a risk factor for JCV seroconversion or elevated JCV antibody index.
- To evaluate the utility of smoking status in refining PML risk stratification for natalizumab-treated MS patients.
Main Methods:
- Retrospective analysis of a cohort of 200 MS patients from the Medical University of Innsbruck.
- Screening of patient database for smoking status (current and former smokers) and anti-JCV antibody index.
- Anti-JCV antibody index determined by two-step ELISA.
Main Results:
- No statistically significant association was found between smoking status (current or former) and JCV infection.
- Smoking status did not correlate with the level of anti-JCV antibody index.
- The study cohort comprised 36% current smokers and 6% former smokers.
Conclusions:
- Smoking does not appear to be a risk factor for JCV infection in multiple sclerosis patients.
- Smoking status is not a suitable marker for stratifying PML risk in MS patients treated with natalizumab.
- Further research may be needed to identify additional reliable biomarkers for PML risk stratification.
Related Concept Videos
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
What are Viruses?
Introduction to Virus
Viruses of Archaea
Viruses with RNA Genomes
Patient-centered Care

